Magnetic Resonance (MR) Spectroscopy of Breast Cancer Tissue

NCT00184210 | Terminated

• 1 other identifier: 154080/I30
• Study Type: observational
• Target: 1,000
• Locations: 1 country
• Sites: 1

Brief Summary

Breast cancer tissue is collected from women undergoing scheduled surgery for breast cancer. The tissue specimen are analyzed by MR spectroscopy. After MR, the intact tissue specimen can be analyzed by other methods, such as histopathology. The MR spectral profiles are compared to clinical findings such as the patients diagnosis, lymph node status and tumor size.

Conditions

Breast Neoplasms

Keywords

Magnetic Resonance Spectroscopy

Outcome Measures

Primary Outcomes (1)

• MRimage of breast cancer tissue

  0 hour

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

women in surgery for breast cancer

You may qualify if:

• Palpable breast cancer lesion

Sponsors & Collaborators

• Norwegian University of Science and Technology: lead
• The Research Council of Norway: collaborator
• The Norwegian Women´s Public Health Association: collaborator

Study Sites (1)

Norwegian University of Technology and Science

Trondheim, 7491, Norway

Location

Related Publications (5)

• Sitter B, Sonnewald U, Spraul M, Fjosne HE, Gribbestad IS. High-resolution magic angle spinning MRS of breast cancer tissue. NMR Biomed. 2002 Aug;15(5):327-37. doi: 10.1002/nbm.775.

  PMID: 12203224 RESULT

• Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed. 2006 Feb;19(1):30-40. doi: 10.1002/nbm.992.

  PMID: 16229059 RESULT

• Bathen TF, Jensen LR, Sitter B, Fjosne HE, Halgunset J, Axelson DE, Gribbestad IS, Lundgren S. MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status. Breast Cancer Res Treat. 2007 Aug;104(2):181-9. doi: 10.1007/s10549-006-9400-z. Epub 2006 Oct 24.

  PMID: 17061040 RESULT

• Sitter B, Bathen TF, Singstad TE, Fjosne HE, Lundgren S, Halgunset J, Gribbestad IS. Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy. NMR Biomed. 2010 May;23(4):424-31. doi: 10.1002/nbm.1478. Epub 2010 Jan 25.

  PMID: 20101607 RESULT

• Giskeodegard GF, Grinde MT, Sitter B, Axelson DE, Lundgren S, Fjosne HE, Dahl S, Gribbestad IS, Bathen TF. Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics. J Proteome Res. 2010 Feb 5;9(2):972-9. doi: 10.1021/pr9008783.

  PMID: 19994911 RESULT

Biospecimen

Retention: SAMPLES WITH DNA

tissue

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Tone F Bathen, PhD

  Norwegian University of Technology and Science

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 12, 2005
• First Posted: September 16, 2005
• Study Start: January 1, 2000
• Primary Completion: December 1, 2020
• Study Completion: December 1, 2020
• Last Updated: March 22, 2021

Record last verified: 2021-03

Locations

NO (1)